Continuing Pharmacy Education / CE Master List / Breathing Beyond the Barriers: The Latest 2024 GOLD Report-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Breathing Beyond the Barriers: The Latest 2024 GOLD Report-RECORDED WEBINAR

Learning Objectives

The activity will cover the following learning objectives for Pharmacists:
  • Recognize new definitions and parameters surrounding COPD
  • Explain updates coinciding with screening and diagnosis for COPD
  • Differentiate inhaler selection for COPD management corresponding to disease severity and patient specific factors
  • Discuss non-pharmacotherapy strategies for COPD management
  • Apply the 2024 GOLD standards to patient cases

Activity Release Dates

Released:  May 30, 2024
Expires:  May 30, 2027

Course Fee

$10 Pharmacist

ACPE UAN Code

 0009-9999-24-023-H01-P

Session Code

24EH23-XFT24

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-9999-24-023-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Maria Miceli, PharmD
PGY-1 Resident
Emerson Hospital,
Concord, MA

Meagan Coughlin, PharmD, BCGP
Transitions of Care Pharmacy Specialist
Emerson Hospital
Concord, MA

Faculty Disclosure

  • Drs. Micelli and Coughlin do not have any relationships with ineligible companies.

 

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test Pharmacist

<< Breathing Beyond the Barriers: The Latest 2024 GOLD Report – Recorded Webinar>>

Pharmacist Post-test

After completing this continuing education activity, pharmacists will be able to

• Recognize new definitions and parameters surrounding COPD
• Explain updates coinciding with screening and diagnosis for COPD
• Differentiate inhaler selection for COPD management corresponding to disease severity and patient specific factors
• Discuss non-pharmacotherapy strategies for COPD management
• Apply the 2024 GOLD standards to patient cases

1. Hyperinflation of the lungs is a newly recognized contributory factor of COPD. Which of the following is true regarding hyperinflation?
a. Hyperinflation results in a decrease in lung gas volume compared to normal values at the end of spontaneous expiration
b. Hyperinflation is primarily due to increased elastic recoil of the lungs
c. Hyperinflation can occur at rest or during exercise activities

2. Which of the following is a screening tool that can be used to assess COPD symptom severity?
a. Modified British Medical Research Council (mMRC) dyspnea scale
b. World Health Organization Lung Function Classification scale
c. Global Initiative for Chronic Obstructive Lung Disease Airflow Limitation Test

3. You are counseling patient ES on the proper use of an albuterol DPI. ES states that she has noticed no improvement in symptoms since starting her medication. She is concerned that she may not be able to inhale with enough force to administer the medication effectively. Which of the following recommendations can be made to improve medication delivery?
a. Stop the albuterol DPI and switch to albuterol tablets as tablets are more effective than inhalers.
b. Consider switching from an albuterol DPI to an albuterol MDI and provide a spacer.
c. Stop the albuterol and upgrade to a LABA DPI to increase the efficacy of her medication.

4. Patient DK is currently hospitalized for his second moderate exacerbation of COPD this year. DK’s current blood eosinophil count is 240 cells/mcL. Which of the following treatment regimens is appropriate?
a. LABA + LAMA
b. Bronchodilator, only
c. LABA + LAMA + ICS

5. According to the CDC, which of the following vaccines is/are recommended in individuals with COPD?
a. PCV20 followed by PCV23
b. Hepatitis A + B vaccine
c. Influenza vaccine

6. Non-pharmacologic strategies for COPD include which of the following?
a. Smoking cessation
b. Limiting physical activity
c. Dietary salt restriction

7. According to the recent GOLD Report, updates in COPD screening include which of the following?
a. GOLD recommends leveraging imaging from lung cancer screening and incidental lung findings for COPD screening.
b. GOLD recommends low dose chest computed tomography for all individuals 50 to 80 years of age.
c. GOLD does not recommend pre-bronchodilator spirometry to investigate obstruction in symptomatic patients.